Diagnosis
• The diagnosis of hypertension is based on repeated reproducible measurements of elevated blood pressure.
• A specific cause of hypertension can be established in only 10-15% of patients: renal artery constriction, coarctation of the aorta, pheochromocytoma, Cushing's disease and primary aldosteronism.
• Patients in whom no specific cause of hypertension can be found are said to have essential hypertension.
• Elevated blood pressure is usually caused by a combination of several abnormalities (multifactorial): genetic inheritance, psychologic stress environmental and dietary factors (increased salt, perhaps decreased potassium or calcium intake).
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Regulation of blood pressure BP= cardiac output × peripheral vascular resistance
• In both normal and hypertensive individuals, blood pressure is maintained by moment-to-moment regulation of cardiac output and peripheral vascular resistance.
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Anatomic sites of blood pressure control
• Arterioles (resistance)
• Venules (capacitance)
• Heart (pump output)
• Kidneys (volume).
• Baroreflexes that are controlled by autonomic nerve system and humoral mechanisms including renin-angiotensin-aldosteron system coordinate these anatomic sites.
• The difference between normal and hypertensive patients is that baroreceptors are set to higher levels. 
Diuretics I
• Dietary sodium restriction has been known for many years to decrease blood pressure in hypertensive patients.
• Dietary control of blood pressure is a relatively nontoxic therapeutic measure and may even be preventive.
• Diuretics lower blood pressure primarily by depleting body sodium stores. Initially they reduce blood pressure by reducing blood volume and cardiac output; peripheral vascular resistance may increase. After 6-8 weeks, cardiac output returns toward normal while peripheric vascular resistance declines.
• Sodium is believed to contribute to vascular resistance due to increases sodium-calcium exchange with a resultant increase in intracellular calcium.
• Some diuretics like indapamide have direct vasodilator properties.
• Amiloride inhibits effects of contractile impulses on vascular smooth muscle with a mechanism independent from its natriuretic effect, which is preventing transmembrane and intracellular calcium movements.
Diuretics II
• Diuretics are effective in lowering blood pressure by 10-15 mm Hg in most patients and often provide adequate treatment for mild or moderate essential hypertension when used alone. In more severe hypertension diuretics are used in combination with sympathoplegic and vasodilator drugs to control the tendency toward sodium retention caused by these agents.
• For most patients thiazide diuretics are appropriate when renal and cardiac function is normal.
Diuretics III
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• More powerful diuretics (loop agents) are necessary in severe hypertension, renal insufficiency (GFR< 30-40 ml/min), and in cardiac failure or cirrhosis where sodium retention is marked.
• Potassium-sparing diuretics are useful both to avoid excessive potassium depletion, particularly in patients taking digitalis and to enhance the natriuretic effects of other diuretics.
Diuretics IV
• The most common is potassium depletion, which is especially important in persons taking digitalis, those who have chronic arrhythmias or those with acute myocardial infarction. Restriction of sodium intake may minimize potassium loss.
• Diuretics may also cause magnesium depletion, impair glucose tolerance and increase serum lipid concentrations.
• They may increase uric acid concentration and precipitate gout. 
Propranolol (continued)
• It has significant first-pass hepatic inactivation.
• The principal toxicity occur in patients with reduced myocardial reserve, asthma, peripheral vascular insufficiency and diabetes when discontinued after prolonged use, some patients experience a withdrawal syndrome, manifested by nervousness, tachycardia, increased intensity of angina or increased blood pressure.
• It may increase plasma triglycerides and reduce HDL.
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Other β-blocker agents I
• Metoprolol: It is approximately equipotent to propranolol in inhibiting stimulation of β 1 receptors, but 50 to 100 fold less potent than propranolol in blocking β 2 receptors. This relative cardioselectivity may be advantageous in patients who also suffer from asthma, diabetes or peripheral vascular disease.
• Nadolol and carteolol are also non-selective. They are not metabolized and are excreted in the urine.
• Atenolol is β 1 selective and not metabolized.
• Betaxolol and bisoprolol are β 1 selective, they are metabolized in the liver but their half-life is long.
• Pindolol, acetobutolol, penbutolol: They are partial agonists (i.e. ISA). Probably they have agonist activity on β 2 receptors rather than antagonism.
Other β-blocker agents II
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• Labetalol and carvedilol:
• Labetalol has 4 stereoisomers.
• Two of these isomers are inactive, one β blocker and one α blocker.
• Carvedilol has 2 stereoisomers.
• S isomer α and β blocker • R isomer α blocker.
• The combined α and β receptor blockade with labetalol makes it useful in pheochromocytoma and hypertensive emergencies.
• Preliminary studies suggest that carvedilol may be useful in some cases of congestive heart failure.
Other β-blocker agents III α 1 blockers I
• Prazosin, terazosin, doxazosin: They are α 1 selective blockers. α 2 receptors are intact thus feedback mechanisms for noradrenalin remains intact and less reflex tachycardia is observed than nonselective α-blockers.
• They produce their antihypertensive effects by blocking α 1 receptors in arterioles and venules. The drugs are more effective when used in combination with other agents, such as a beta-blocker and a diuretic than when use alone.
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• Treatment should be initiated with a low dose to prevent postural hypotension and syncope administered at bedtime. Unlike diuretics and beta-blockers, the α 1 -blockers do not adversely and may even beneficially affect plasma lipid profiles.
• Other selective α 1 -blockers for antihypertensive use are: alfuzosin, tamsulosin, indoramin, and urapidil (it is also a weak α 2 -agonist, 5-HT 1A -agonist and weak β 1 antagonist).
α 1 blockers I Non-selective α-blockers
• Phentolamine and phenoxybenzamine are non-selective α-blockers.
• They are useful in diagnosis and treatment of pheochromocytoma and in other clinical situations associated with exaggerated release of catecholamines (eg. in clonidine withdrawal syndrome combined with propranolol).
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Centrally acting sympathoplegic drugs I
• Methyldopa: It is an analog of L-dopa and is converted to α-methyldopamine and α-methylnorepinephrine, which are false transmitters. Methyldopa's antihypertensive action appears to be due to stimulation of central α 2 receptors. • It may result in postural hypotension one of its advantage is that it decreases renal vascular resistance.
• Clonidine is an α 2 and imidazoline receptor agonist. Its antihypertensive action is due to decrease in heart rate, and decrease in cardiac output because of relaxation of capacitance vessels. Renal vascular resistance also decreases.
• After clonidine application circulating catecholamine levels decrease (chemical sympatectomy).
• Guanabenz and guanfacine are centrally active antihypertensive agents that share the central alpha-adrenoceptor-stimulating effects of clonidine.
Centrally acting sympathoplegic drugs II
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Ganglion-blocking agents
• They act by inhibiting the stimulating action of acetylcholine on postganglionic autonomic neurons.
• Trimethaphan: It is used intravenously in hypertensive crisis, acute aorta dissection and controlled hypotension in neurosurgery. It has rapid and short action.
• These drugs decrease blood pressure by inhibiting the release of noradrenaline from sympathetic neurons.
• Guanethidine, bethanidine, debrisoquin: They are transported across membrane by uptake-1. They are concentrated in transmitter vesicles and cause gradual depletion of norepinephrine. Uptake-1 inhibitors such as cocaine, amphetamine, tricyclic antidepressants decrease their effects. They increase sensitivity to the hypertensive effects of exogenously administered sympathomimetic amines.
• Reserpine: It blocks the ability of aminergic transmitter vesicles to take up and store biogenic amines. It was widely used previously. It may result in depression.
• It has no indication in modern antihypertensive therapy but found in the prescriptions of old doctors.
• Pargyline: It is a MAO inhibitor and is believed to increase the concentration of an ineffective false transmitter. It has no modern use.
Adrenergic neuron blockers II
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Direct vasodilators
• Calcium channel blockers • Hydralazine • Minoxidil • Sodium nitroprusside • Diazoxide
• They are blockers of L-type calcium channels.
• Verapamil: It is cardioselective.
• Dihydropyridines (amlodipine, felodipine, isradipine, nicardipine, nisoldipine): They are vascular smooth muscle selective.
• Diltiazem: Intermediate
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• Verapamil may decrease heart rate and cardiac output • Dihydropyridines are minimally cardiodepressive with reflex sympathetic activations and mild tachycardia, cardiac output is preserved or even slightly increased.
• With the use of short acting nifedipine, there is an increase in MI and mortality.
• In the treatment of hypertension sustained release nifedipine preparations and drugs with long plasma half-life control blood pressure safely.
Calcium channel blockers II
Other direct vasodilators I
• Hydralazine: It relaxes arterioles but not veins. When used alone tachyphlaxis to hypertensive effects develops rapidly. With combination therapy it may be used particularly in severe hypertension.
• Its bioavailability is low. There is genetic variability for its metabolism.
Dosage should be regulated according to individual responses.
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• Minoxidil: It is a very efficacious orally active vasodilator. Its effect results from the opening of potassium channels in smooth muscle membrane. It dilates arterioles like hydralazine. Clinical responses are better than hydralazine and particularly in renal failure it should be preferred.
• Topical minoxidil (Rogaine) is used as a stimulant to hair growth for correction of baldness.
• If it is not combined with a beta-blocker and a loop diuretic, sympathetic stimulation, angina, sodium and fluid retention may occur.
Other direct vasodilators II
• Diazoxide: It is an effective and relatively long-acting parenterally administered arteriolar dilator. It opens potassium channels like minoxidil. Its antihypertensive effect initiates within 5 min. and lasts for 4-12 hours.
• It inhibits insulin release from pancreas and causes renal salt and water retention.
Other direct vasodilators III
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• Sodium nitroprusside: It is a powerful parenterally administered vasodilator that is used in treating hypertensive emergencies as well as severe cardiac failure.
• It dilates both arterioles and venules. The action occurs as a result of activation of guanylyl cyclase. The result is increased intracellular cGMP, which relates vascular smooth muscle.
Other direct vasodilators IV Sodium nitroprusside (continued)
• In the absence of cardiac failure, blood pressure decreases, owing to decreased vascular resistance, while cardiac output changes slightly. In patients with cardiac failure, cardiac output increases owing to afterload reduction.
• It is a complex of iron, cyanide groups. With infusions more than 10 μg/kg/min, cyanide toxicity occurs. metabolic acidosis, arrhythmia, hypotension, dead.
• Aqueus solution is sensitive to light.
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Inhibitors of angiotensin
Angiotensin converting enzyme (ACE) inhibitors
• Captopril and other drugs in this class inhibit the converting enzyme that hydrolyzes angiotensin I to angiotensin II. • The same enzyme inactivates bradykinin a potent vasodilator that works at least in part by stimulating release of nitric oxide and prostacyclin. Angiotensin II is vasoconstrictor and has salt and water retaining activity via aldosteron secretion.
ACE inhibitors I
• Captopril and lisinopril are orally active agents.
• Enapril is a prodrog and is converted to active form enaprilat in liver. Enaprilat is only available in IV form for hypertensive emergencies.
• Benazepril, fosinopril, moexepril, quinapril and ramipril are all prodrugs and hydrolyzed in liver to active forms.
• ACE inhibitors decrease blood pressure by decreasing peripheral vascular resistance. Cardiac output and heart rate do not change significantly. As they do not cause reflex sympathetic activation, they are safe in patients with ischemic heart disease.
• The absence of reflex tachycardia may be due to downward resetting of the baroreceptors or to enhanced parasympathetic activity.
ACE inhibitors II
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• They are particularly useful in treating patients with diabetic nephropathy, diminishing proteinuria and stabilizing renal function. They are also useful in congestive heart failure and after MI. • All ACE inhibitors are excreted via kidneys except fosinopril and moexipril.
• In hypervolemic patients (due to diuretics, salt restriction, GI fluid loss), first doses may result in severe hypotension. Other adverse effects include acute renal failure, hyperkalemia, dry cough, sometimes wheezing and angioedema (dry cough and angioedema due to increased effects of bradykinin).
ACE inhibitors III
• ACE inhibitors are contraindicated during the second and third trimesters of pregnancy because of the risk of fetal hypotension, anuria and renal failure, sometimes associated with fetal malformations or death.
• Potassium supplements or potassium sparing diuretics can result in hyperkalemia.
• NSAI drugs may impair hypotensive effects by blocking bradykininmediated vasodilation which is at least in part PG mediated.
